Payment overview · 2025
General Payments
$633.76
34 reported records · 8 companies
Healthcare provider profile · identity verified
Aaron Pfau, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · LAS CRUCES, NM · NPI 1659683944
Verified facts
What the public records show
CMS Open Payments records show Aaron Pfau, D.O. received $633.76 in general payments during 2025 across 34 reported records.
AstraZeneca Pharmaceuticals LP accounted for 43.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $274.44 | 43.3% | 15 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.68 | 22.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.58 | 9.6% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $45.38 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.24 | 6.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.29 | 4.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.18 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.97 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $633.76 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $181.90 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.68 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.04 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $60.58 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.58 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $45.38 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.24 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.18 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 797 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 533 | 150 |
| Lisinopril | Lisinopril | 497 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 460 | 134 |
| Losartan Potassium | Losartan Potassium | 296 | 87 |
| Omeprazole | Omeprazole | 267 | 75 |
| Metformin Hcl | Metformin Hcl | 255 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 79 |
| Gabapentin | Gabapentin | 207 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 67 |
| Simvastatin | Simvastatin | 197 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 173 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 161 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 137 | 37 |
| Allopurinol | Allopurinol | 134 | 43 |
| Escitalopram Oxalate | Escitalopram Oxalate | 133 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 124 | 25 |
| Alprazolam | Alprazolam | 117 | 28 |
| Montelukast Sodium | Montelukast Sodium | 111 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 47 |
| Meloxicam | Meloxicam | 84 | 29 |
| Finasteride | Finasteride | 82 | 26 |
| Jardiance | Empagliflozin | 77 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 71 | 38 |
| Glipizide | Glipizide | 70 | 19 |
| Sertraline Hcl | Sertraline Hcl | 70 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 69 | 21 |
| Synthroid | Levothyroxine Sodium | 67 | 16 |
| Trulicity | Dulaglutide | 67 | 13 |
| Famotidine | Famotidine | 66 | 25 |
| Furosemide | Furosemide | 65 | 22 |
| Trazodone Hcl | Trazodone Hcl | 65 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 19 |
| Eliquis | Apixaban | 59 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 20 |
| Potassium Chloride | Potassium Chloride | 57 | 19 |
| Farxiga | Dapagliflozin Propanediol | 54 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 12 |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Mounjaro | Tirzepatide | 45 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 44 | 12 |
| Ozempic | Semaglutide | 44 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 13 |
| Alendronate Sodium | Alendronate Sodium | 42 | 12 |
| Bupropion Xl | Bupropion Hcl | 42 | 14 |
| Lorazepam | Lorazepam | 42 | suppressed |
| Spironolactone | Spironolactone | 42 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Naproxen | Naproxen | 40 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Baclofen | Baclofen | 37 | 14 |
| Atenolol | Atenolol | 36 | 12 |
| Ondansetron Odt | Ondansetron | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Lovastatin | Lovastatin | 33 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 14 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 11 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | 11 |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Belsomra | Suvorexant | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Azithromycin | Azithromycin | 24 | 22 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Irbesartan | Irbesartan | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | 16 |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Prednisone | Prednisone | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $633.76 · 34 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, Cologuard Collection Kit, FARXIGA, MOUNJARO, OTEZLA, PAXLOVID, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error